Page 16 - Read Online

Page 10 of 11 Genovesi et al. Vessel Plus 2021;5:50 https://dx.doi.org/10.20517/2574-1209.2021.67

Med Biol 2021;9:71-5. DOI PubMed PMC
13. Tuominen H, Haarala A, Tikkakoski A, Kähönen M, Nikus K, Sipilä K. 18-FDG-PET in a patient cohort suspected for cardiac
sarcoidosis: Right ventricular uptake is associated with pathological uptake in mediastinal lymph nodes. J Nucl Cardiol 2020;27:109-
17. DOI PubMed
14. Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic
innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29:168-74. DOI PubMed
15. Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic
innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9. DOI PubMed
16. Lekakis J, Dimopoulos MA, Prassopoulos V, et al. Myocardial adrenergic denervation in patients with primary (AL) amyloidosis.
Amyloid 2003;10:117-20. DOI PubMed
17. Noordzij W, Glaudemans AW, van Rheenen RW, et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac
sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:1609-17. DOI PubMed PMC
18. Coutinho MC, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic
marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging 2013;6:627-36. DOI PubMed
19. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P
component. N Engl J Med 1990;323:508-13. DOI PubMed
20. Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in
patients with amyloidosis. Am J Med 2006;119:355.e15-24. DOI PubMed
21. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m
labelled aprotinin. Eur J Nucl Med 1995;22:1393-401. DOI PubMed
22. Schaadt BK, Hendel HW, Gimsing P, Jønsson V, Pedersen H, et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med
2003;44:177-83. PubMed
23. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol
2004;55:306-19. DOI PubMed
24. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med
2013;54:213-20. DOI PubMed
25. Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med
2009;50:1887-94. DOI PubMed PMC
26. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45
(florbetapir [corrected] F 18). J Nucl Med 2010;51:913-20. DOI PubMed PMC
27. Yang L, Rieves D, Ganley C. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med 2012;367:885-7. DOI
PubMed
18
28. Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using F-florbetapir positron emission tomography.
Eur J Nucl Med Mol Imaging 2014;41:1652-62. DOI PubMed
29. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive
impairment: a phase 2 trial. Ann Neurol 2010;68:319-29. DOI PubMed
30. Lhommel R, Sempoux C, Ivanoiu A, Michaux L, Gerber B. Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis? Clin
Nucl Med 2014;39:747-9. DOI PubMed
18
31. Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using F-flutemetamol positron emission
tomography. Ann Nucl Med 2019;33:624-8. DOI PubMed
18
32. Möckelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundström T. Quantification of cardiac amyloid with [ F]Flutemetamol in
patients with V30M hereditary transthyretin amyloidosis. Amyloid 2020;27:191-9. DOI
33. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer:
proof of mechanism. Lancet Neurol 2008;7:129-35. DOI PubMed
34. Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study. J Nucl Med
2016;57:1733-9. DOI PubMed
18
35. Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with F-Florbetaben-PET/CT in comparison to
echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging 2019;46:1407-16. DOI PubMed
36. Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-Florbetaben PET/CT for Differential diagnosis among cardiac immunoglobulin light
chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging 2021;14:246-55. DOI PubMed
37. Kula R, Engel W, Line B. Scanning for soft-tissue amyloid. Lancet 1977;309:92-3. DOI PubMed
38. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. DOI PubMed
39. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid
scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8. DOI PubMed
40. Kristen AV, Haufe S, Schonland SO, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with
senile systemic amyloidosis. Int J Cardiol 2013;164:179-84. DOI PubMed
41. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-
related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70. DOI PubMed
42. Falk RH, Lee VW, Rubinow A, Hood WB, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing
cardiac amyloidosis. Am J Cardiol 1983;51:826-30. DOI PubMed